The
Malaysia Dengue Treatment Market is anticipated to grow significantly in the
projected period of 2028. The increasing prevalence of dengue in Malaysia is
one of the key factors driving the growth of the Dengue Treatment Drugs market.
Malaysia is a country in Southeast Asia known for its diverse population,
tropical climate, and lush landscapes. However, in recent years, the country
has faced a growing threat from dengue fever, a mosquito-borne disease that can
cause severe flu-like symptoms and, in some cases, be fatal. As a result, the
demand for dengue treatment drugs has been increasing in the country, and it is
expected to continue growing in the coming years.
The
dengue virus is the source of dengue fever, a mosquito-transmitted tropical
disease. Symptoms usually appear three to fourteen days after infection and can
include a high fever, headache, nausea, discomfort in the muscles and joints,
as well as a typical skin rash and itching. Recovery usually takes two to seven
days. In a small percentage of cases, the illness progresses into a more severe
form of dengue hemorrhagic fever, which causes bleeding, low blood platelet
counts, and blood plasma leakage, or dengue shock syndrome, which causes
dangerously low blood pressure. Aedes aegypti is the main species of female
mosquitoes in the Aedes genus that transmit dengue. The virus has five
different serotypes; infection with one usually confers lifetime immunity
against that type, but only temporary immunity to the others. The risk of
serious consequences rises when a new type of infection develops later. Several
tests, including those that look for antibodies to the virus or its RNA, can be
used to confirm the diagnosis.
According
to CodeBlue Social Health Analytics, the mortality rate from dengue
complications increased by 131.6 percent from 19 deaths in 2021 to 44 deaths in
2022. Additionally, increasing government initiatives are leading to increased
awareness about dengue prevalence and prevention among the people of Malaysia.
For instance, to lead the fight against dengue, the Malaysian Ministry of
Health and the Drugs for Neglected Diseases initiative have joined forces,
which is expected to further grow the Malaysia Dengue Treatment Market. The
rise in dengue fever cases during the COVID-19 pandemic and the mobility
control order (MCO) made it imperative to examine how the general public can
prevent the disease, leading to the expansion of the Malaysia Dengue Treatment
Market.
Rising Prevalence of Dengue is Booming the Malaysia Dengue
Treatment Market
Malaysia
is one such country that has been grappling with the burden of dengue for
several years. In recent years, the prevalence of dengue in Malaysia has been
increasing at an alarming rate, which has led to a surge in demand for dengue
treatment drugs. According to the National Library of Medicine, with 397.71
cases per 100,000 people, dengue fever has the highest incidence rate of any infectious
disease in Malaysia. Selangor, Wilayah Persekutuan Kuala Lumpur, and Johor are
the three Malaysian states with the highest number of reported cases of dengue
fever, which is often an urban disease. The situation in Malaysia is worsened
by poor clinical management and unfinished vector control operations. The need
for the creation of a long-lasting, reasonably priced dengue vaccine that is
effective against all infecting serotypes is growing in light of the potential
deadly dengue pandemic. Clinical trials are currently testing a number of
vaccine candidates, but concerns about serotype interference, insufficient protection,
and dose adequacy have been raised. Production of local vaccines should be
taken into consideration in conjunction with government efforts to combat
dengue, rather than relying solely on outsourcing.
The majority of dengue fever
cases can be managed with painkillers at home. The best way to avoid getting
dengue is to avoid mosquito bites. Dengue does not have a specific treatment.
Treatment of pain symptoms is the main priority. To manage pain, acetaminophen
(paracetamol) is frequently used. Ibuprofen and aspirin, two non-steroidal
anti-inflammatory medications, are avoided because they raise the chance of
bleeding. For those who have experienced dengue at least once and reside in
areas where the illness is widespread, there is a vaccine called Dengvaxia.
Hospitalization is frequently required for patients with severe dengue, thus
augmenting the growth of the Malaysia Dengue Treatment Market. The growing
awareness about the importance of Dengue Treatment Drugs and the availability
of advanced diagnostic technologies are also driving the Malaysia Dengue
Treatment Market. The Malaysian government's efforts to tackle the dengue
outbreak are expected to further boost the demand for dengue treatment drugs in
the coming years. This presents a significant opportunity for pharmaceutical
companies to invest in the development of new and effective dengue treatment
drugs, thereby propelling the growth of the Malaysia Dengue Treatment Market.
Download Free Sample Report
Rising Technological Advancements Leads to Rising Demand
for Malaysia Dengue Treatment Drugs
The Malaysia dengue treatment market is projected to
witness significant growth in the coming years, driven by increasing
technological advancements, leading to the expansion of the market. Recent
developments in point-of-care (POC) and molecular diagnostics, as well as in
wireless communication, low-power microelectronics, and wearable sensors, have
created new opportunities for the management, clinical monitoring, and
real-time surveillance of dengue. According to the International Trade
Administration, the Ministry of Health (MOH) has received USD7.7 billion from
the government for operating and development costs. With advancements in
technology, researchers are continuously developing new and innovative ways to
tackle dengue fever. One of the most promising developments is the use of
nanotechnology in the treatment of dengue. Nanoparticles have unique properties
that make them ideal for drug delivery, and researchers are exploring ways to
use them to enhance the efficacy of existing dengue drugs. For example,
nanoparticles can be used to increase the bioavailability of drugs, allowing
them to reach their target more effectively and efficiently. In addition to
nanotechnology, other technological advancements are also contributing to the
growth of the Malaysian dengue treatment drugs market. For instance, the use of
artificial intelligence (AI) in drug development is gaining traction. AI can be
used to analyze vast amounts of data and identify patterns that would be
difficult for humans to detect. This can help researchers identify new drug
targets and develop more effective drugs for dengue fever. Another
technological advancement driving the Malaysian dengue treatment market is the
development of new diagnostic tools. Rapid diagnostic tests (RDTs) are becoming
increasingly popular for the diagnosis of dengue fever, as they provide quick
and accurate results. Moreover, the development of point-of-care testing (POCT)
devices has enabled healthcare professionals to diagnose dengue fever in remote
or rural areas where laboratory facilities are limited, which is expected to
boost the Malaysia Dengue Treatment Market.
Recent Developments
- In October 2023, an
experimental dengue drug created by Johnson & Johnson showed promise
against all four types of the virus in mice and prevented infection from two
types in monkeys. JNJ-1802, which is an early-stage trial of the experimental
treatment, has already been completed. A randomized Phase II clinical trial for
the drug has been initiated by the company. Johnson & Johnson is using
artificial intelligence (AI) to forecast dengue hotspots, create predictive
models for dengue incidence, and speed up trial recruitment and site sourcing in
addition to developing JNJ-18.
Mergers and Acquisitions
- In June 2021, in an effort to
reimagine global health and increase access to healthcare and medications,
Novartis and Hewlett Packard Enterprise (NYSE: HPE) announced a partnership
that aims to accelerate the use of data and digital technologies within
Novartis' initiatives. To assist authorities in proactively deploying response
strategies targeting at-risk populations, Novartis and Hewlett Packard
Enterprise aim to jointly develop publicly available insights. This will help
address the growing threat of dengue fever.
Market Segmentation
Malaysia Dengue
Treatment Market is segmented into Type, Route of Administration, End-users, Region and Competitive Landscape. Based on Type, the market
is divided into Drug and
Vaccine. Based on Route of Administration, Malaysia
Dengue Treatment Market is categorized into Oral and Parenteral. Based on End-users,
the market is categorized into Hospitals, Specialty Clinic,
Homecare, and Others. Based on Region, the Malaysia Dengue Treatment Market
is segmented into the East Malaysia and West Malaysia.
Company Profiles
Johnson & Johnson, Novartis Corporation (Malaysia)
Sdn. Bhd., Otsuka Pharmaceuticals (Malaysia) Sdn. Bhd., GSK Malaysia, Roche
Holding Ag Malaysia., Sanofi-Aventis (Malaysia) Sdn. Bhd, Bayer Co. (Malaysia)
Sdn Bhd, Merck Sdn Bhd are some of the key players in Malaysia Dengue Treatment
Market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast,
company shares, competitive landscape, growth factors, and trends
|
|
Segments covered
|
Type
Route of Administration
End-users
|
|
Country scope
|
The East
Malaysia and The West Malaysia
|
|
Key companies profiled
|
Johnson
& Johnson, Novartis Corporation (Malaysia) Sdn. Bhd., Otsuka Pharmaceuticals
(Malaysia) Sdn. Bhd., GSK Malaysia, Roche Holding Ag Malaysia., Sanofi-Aventis
(Malaysia) Sdn. Bhd, Bayer Co. (Malaysia) Sdn Bhd, Merck Sdn Bhd
|
|
Customization scope
|
10% free report customization with purchase.
Addition or alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized
purchase options to meet your exact research needs.
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report
Scope:
In this
report, the Malaysia Dengue Treatment
Market has been segmented into the following categories, in addition to
the industry trends, which have also been detailed below:
- Malaysia
Dengue Treatment Market, By Type:
- Malaysia
Dengue Treatment Market, By Route of Administration:
- Malaysia
Dengue Treatment Market, By End-users:
- Hospitals
- Specialty
Clinic
- Homecare
- Others
- Malaysia
Dengue Treatment Market, By Region:
- East Malaysia
- West Malaysia
Competitive
landscape
Company
Profiles: Detailed
analysis of the major companies in Malaysia Dengue Treatment Market.
Available
Customizations:
With the
given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling
of additional market players (up to five).
Malaysia Dengue Treatment Market is an upcoming report
to be released soon. If you wish an early delivery of this report or want to confirm
the date of release, please contact us at [email protected]